Funder: National Institutes of Health
Due Dates: June 17, 2025 (New, Renewal, Resubmission, Revision)
Funding Amounts: Up to $750,000 direct costs per year, for up to 3 years; budgets should reflect actual project needs and rarely exceed this amount.
Summary: Supports translational development of safe, effective, and non-addictive device-based technologies for pain, advancing prototypes to readiness for first-in-human clinical trials.
Key Information: Clinical trials are not allowed; a Gantt chart is required; foreign and domestic applicants are eligible.